Librata Endometrial Ablation Device Treatment to Reduce Menstrual Blood Loss

Candidates for this study must meet ALL of the following criteria: * Refractory menorrhagia with no organic cause * Female subject from (and including) age 25 to 50 years * Uterine sound measurement ≥6.0 cm to ≤ 10.0cm (external os to fundus). * A minimum menstrual blood loss * for subjects not using medical therapy, a Menstrual Pictogram(MP) score of ≥150 for two baseline cycles within three months prior to treatment OR * MP score ≥150 for one month for women who either had * at least 3 prior months documented failed medical therapy; or * had a contraindication to medical therapy; or * refused medical therapy * Premenopausal at enrollment as determined by FSH measurement ≤ 40 IU/L * Not pregnant and no desire to conceive at any time * Subject agrees to use a reliable form of contraception. If a hormonal birth control method is used, the subject must have been on said method for ≥ 3 months prior to enrollment and agrees to remain on the same hormonal regimen through their study participation. * Able to provide written informed consent using a form that has been approved by the reviewing IRB/EC * Subject agrees to follow-up visits and data collection requirements * Subject who is literate or demonstrates an understanding on how to use the Menstrual Pictogram (MP) diary 4.1.1. EXCLUSION CRITERIA To be enrolled, candidates should NOT meet any exclusion criterion: * Pregnancy or subject with a desire to become pregnant * Endometrial hyperplasia as confirmed by histology * Presence of active endometritis * Active pelvic inflammatory disease * Active sexually transmitted disease (STD), at the time of ablation. o Note: Treatment of STD documented in the chart serves as sufficient evidence of infection resolution. Subject may be considered for study enrollment. * Presence of bacteremia, sepsis, or other active systemic infection * Active infection of the genitals, vagina, cervix, uterus or urinary tract at the time of the procedure * Known/suspected gynecological malignancy within the past 5 years * Known clotting defects or bleeding disorders * Untreated/unevaluated cervical dysplasia (except CIN I) * Known/suspected abdominal/pelvic cancer * Prior uterine surgery (except low segment cesarean section) that interrupts the integrity of the uterine wall (e.g., myomectomy or classical cesarean section) * Previous endometrial ablation procedure * Currently on medications that could thin the myometrial muscle, such as long-term steroid use (except inhaler or nasal therapy for asthma) * Currently on anticoagulants * Abnormal or obstructed cavity as confirmed by transvaginal ultrasound +/- hysteroscopy - specifically: 1. Septate or bicornuate uterus or other congenital malformation of the uterine cavity 2. Submucosal fibroids (grade 0-2) which protrude \>1cm into the uterine cavity 3. Polyps \>2 cm in maximum diameter 4. Any intramural myoma \> 3 cm or which distorts the uterine cavity * Presence of an intrauterine device (IUD) which the subject unwilling to have removed at the time of the operative visit * Presence of an implanted contraceptive device (e.g. Essure or Adiana). * Subject not currently on hormonal birth control therapy and unwilling to use a non-hormonal birth control post-ablation * Subject wanting concomitant hysteroscopic sterilization * Subject who is within 6-weeks post-partum * Any general health condition which, in the opinion of the Investigator, could represent an increased risk for the subject * Any subject who is currently participating in the primary endpoint phase of an on-going investigational drug or device study or intends future participation in any other research of an investigational drug or device during the primary endpoint phase of this study